JPWO2013118842A1 - ベンゾチオフェン化合物、該化合物を有効成分とするオルタナティブオートファジー誘導剤及び抗癌剤、並びに抗癌活性を有する化合物をスクリーニングするための方法 - Google Patents
ベンゾチオフェン化合物、該化合物を有効成分とするオルタナティブオートファジー誘導剤及び抗癌剤、並びに抗癌活性を有する化合物をスクリーニングするための方法 Download PDFInfo
- Publication number
- JPWO2013118842A1 JPWO2013118842A1 JP2013557579A JP2013557579A JPWO2013118842A1 JP WO2013118842 A1 JPWO2013118842 A1 JP WO2013118842A1 JP 2013557579 A JP2013557579 A JP 2013557579A JP 2013557579 A JP2013557579 A JP 2013557579A JP WO2013118842 A1 JPWO2013118842 A1 JP WO2013118842A1
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- branched
- linear
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 265
- -1 Benzothiophene compound Chemical class 0.000 title claims abstract description 136
- 230000004900 autophagic degradation Effects 0.000 title claims abstract description 112
- FCEHBMOGCRZNNI-UHFFFAOYSA-N thianaphthalene Natural products C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 title claims abstract description 99
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims description 114
- 239000002246 antineoplastic agent Substances 0.000 title claims description 27
- 238000012216 screening Methods 0.000 title claims description 22
- 239000000411 inducer Substances 0.000 title claims description 16
- 239000004480 active ingredient Substances 0.000 title claims description 12
- 230000001939 inductive effect Effects 0.000 claims abstract description 84
- 230000000694 effects Effects 0.000 claims abstract description 68
- 108010045758 lysosomal proteins Proteins 0.000 claims abstract description 31
- 102000034287 fluorescent proteins Human genes 0.000 claims abstract description 15
- 108091006047 fluorescent proteins Proteins 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 163
- 206010028980 Neoplasm Diseases 0.000 claims description 137
- 201000011510 cancer Diseases 0.000 claims description 105
- 125000004432 carbon atom Chemical group C* 0.000 claims description 70
- 125000001424 substituent group Chemical group 0.000 claims description 65
- 230000030833 cell death Effects 0.000 claims description 46
- 238000012360 testing method Methods 0.000 claims description 41
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 38
- 125000004122 cyclic group Chemical group 0.000 claims description 38
- 230000004083 survival effect Effects 0.000 claims description 32
- 125000005843 halogen group Chemical group 0.000 claims description 31
- 125000006618 5- to 10-membered aromatic heterocyclic group Chemical group 0.000 claims description 18
- 125000003277 amino group Chemical group 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000002947 alkylene group Chemical group 0.000 claims description 13
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 13
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 13
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 230000006907 apoptotic process Effects 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 210000004748 cultured cell Anatomy 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 210000003712 lysosome Anatomy 0.000 claims description 6
- 230000001868 lysosomic effect Effects 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 230000004845 protein aggregation Effects 0.000 claims description 2
- 230000035899 viability Effects 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 abstract description 23
- 238000004220 aggregation Methods 0.000 abstract description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 117
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical class ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 100
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 63
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- 239000002904 solvent Substances 0.000 description 26
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 26
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 21
- 238000004809 thin layer chromatography Methods 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 19
- 238000005481 NMR spectroscopy Methods 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 239000012300 argon atmosphere Substances 0.000 description 18
- 238000005259 measurement Methods 0.000 description 18
- 238000001914 filtration Methods 0.000 description 17
- 238000012746 preparative thin layer chromatography Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 101150096483 atg5 gene Proteins 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 13
- CSQPRVLHHWJZIO-UHFFFAOYSA-N ethyl 2-acetamido-6-bromo-7-[2-(diethylamino)ethoxy]-1-benzothiophene-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OCC)=C(NC(C)=O)SC2=C1OCCN(CC)CC CSQPRVLHHWJZIO-UHFFFAOYSA-N 0.000 description 13
- 229910000160 potassium phosphate Inorganic materials 0.000 description 13
- 235000011009 potassium phosphates Nutrition 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 12
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 12
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 230000002950 deficient Effects 0.000 description 10
- 239000013642 negative control Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 238000001308 synthesis method Methods 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 101150117895 LAMP2 gene Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 6
- 229960005420 etoposide Drugs 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 101150102163 ATG7 gene Proteins 0.000 description 5
- 101150048357 Lamp1 gene Proteins 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- 125000003368 amide group Chemical group 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 210000004957 autophagosome Anatomy 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 4
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- LVQQTDJOVUGDGX-UHFFFAOYSA-N ethyl 2-acetamido-6-bromo-7-hydroxy-1-benzothiophene-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OCC)=C(NC(C)=O)SC2=C1O LVQQTDJOVUGDGX-UHFFFAOYSA-N 0.000 description 4
- ATTLXGSJTJVMJV-UHFFFAOYSA-N ethyl 2-acetamido-7-[2-(diethylamino)ethoxy]-6-(4-hydroxyphenyl)-1-benzothiophene-3-carboxylate Chemical compound C=1C=C2C(C(=O)OCC)=C(NC(C)=O)SC2=C(OCCN(CC)CC)C=1C1=CC=C(O)C=C1 ATTLXGSJTJVMJV-UHFFFAOYSA-N 0.000 description 4
- OFAFLZJNJZNFIB-UHFFFAOYSA-N ethyl 2-acetamido-7-[2-(diethylamino)ethoxy]-6-(4-methoxyphenyl)-1-benzothiophene-3-carboxylate Chemical compound C=1C=C2C(C(=O)OCC)=C(NC(C)=O)SC2=C(OCCN(CC)CC)C=1C1=CC=C(OC)C=C1 OFAFLZJNJZNFIB-UHFFFAOYSA-N 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 210000003463 organelle Anatomy 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- MYGDFSFTVVUJHF-UHFFFAOYSA-N ethyl 2-acetamido-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate Chemical compound C1CCCC2=C1SC(NC(C)=O)=C2C(=O)OCC MYGDFSFTVVUJHF-UHFFFAOYSA-N 0.000 description 3
- PVYPZZNDGBZFGH-UHFFFAOYSA-N ethyl 2-acetamido-7-[2-(diethylamino)ethoxy]-6-phenyl-1-benzothiophene-3-carboxylate Chemical compound C=1C=C2C(C(=O)OCC)=C(NC(C)=O)SC2=C(OCCN(CC)CC)C=1C1=CC=CC=C1 PVYPZZNDGBZFGH-UHFFFAOYSA-N 0.000 description 3
- JPJXZTHTKNOGNH-UHFFFAOYSA-N ethyl 2-acetamido-7-oxo-5,6-dihydro-4h-1-benzothiophene-3-carboxylate Chemical compound C1CCC(=O)C2=C1C(C(=O)OCC)=C(NC(C)=O)S2 JPJXZTHTKNOGNH-UHFFFAOYSA-N 0.000 description 3
- GQRWUQMNNIRAQG-UHFFFAOYSA-N ethyl 2-amino-6-bromo-7-[2-(diethylamino)ethoxy]-1-benzothiophene-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OCC)=C(N)SC2=C1OCCN(CC)CC GQRWUQMNNIRAQG-UHFFFAOYSA-N 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 210000001778 pluripotent stem cell Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- DRBLTQNCQJXSNU-UHFFFAOYSA-N 1-benzothiophene-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CSC2=C1 DRBLTQNCQJXSNU-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- RAGSWDIQBBZLLL-UHFFFAOYSA-N 2-chloroethyl(diethyl)azanium;chloride Chemical compound Cl.CCN(CC)CCCl RAGSWDIQBBZLLL-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 102000016614 Autophagy-Related Protein 5 Human genes 0.000 description 2
- 108010092776 Autophagy-Related Protein 5 Proteins 0.000 description 2
- 108010082399 Autophagy-Related Proteins Proteins 0.000 description 2
- 102000003954 Autophagy-Related Proteins Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012445 acidic reagent Substances 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 125000005335 azido alkyl group Chemical group 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000012830 cancer therapeutic Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 201000007455 central nervous system cancer Diseases 0.000 description 2
- 208000025997 central nervous system neoplasm Diseases 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- FNXIDZPJOZCABN-UHFFFAOYSA-N ethyl 2-acetamido-6,6-dibromo-7-oxo-4,5-dihydro-1-benzothiophene-3-carboxylate Chemical compound C1CC(Br)(Br)C(=O)C2=C1C(C(=O)OCC)=C(NC(C)=O)S2 FNXIDZPJOZCABN-UHFFFAOYSA-N 0.000 description 2
- CCLHKGBTHXEKRU-UHFFFAOYSA-N ethyl 2-acetamido-6-[3-azido-5-(azidomethyl)phenyl]-7-[2-(diethylamino)ethoxy]-1-benzothiophene-3-carboxylate Chemical compound C=1C=C2C(C(=O)OCC)=C(NC(C)=O)SC2=C(OCCN(CC)CC)C=1C1=CC(CN=[N+]=[N-])=CC(N=[N+]=[N-])=C1 CCLHKGBTHXEKRU-UHFFFAOYSA-N 0.000 description 2
- WCIGVCGTJGLHIH-UHFFFAOYSA-N ethyl 2-acetamido-7-[2-(diethylamino)ethoxy]-6-(3-methylphenyl)-1-benzothiophene-3-carboxylate Chemical compound C=1C=C2C(C(=O)OCC)=C(NC(C)=O)SC2=C(OCCN(CC)CC)C=1C1=CC=CC(C)=C1 WCIGVCGTJGLHIH-UHFFFAOYSA-N 0.000 description 2
- YEAACSCKBZTAKA-UHFFFAOYSA-N ethyl 2-acetamido-7-[2-(diethylamino)ethoxy]-6-(4-fluorophenyl)-1-benzothiophene-3-carboxylate Chemical compound C=1C=C2C(C(=O)OCC)=C(NC(C)=O)SC2=C(OCCN(CC)CC)C=1C1=CC=C(F)C=C1 YEAACSCKBZTAKA-UHFFFAOYSA-N 0.000 description 2
- YNWVJJHGDRTZJJ-UHFFFAOYSA-N ethyl 2-acetamido-7-[2-(diethylamino)ethoxy]-6-[4-(trifluoromethyl)phenyl]-1-benzothiophene-3-carboxylate Chemical compound C=1C=C2C(C(=O)OCC)=C(NC(C)=O)SC2=C(OCCN(CC)CC)C=1C1=CC=C(C(F)(F)F)C=C1 YNWVJJHGDRTZJJ-UHFFFAOYSA-N 0.000 description 2
- JIWVWHCOWHIRFV-UHFFFAOYSA-N ethyl 2-acetamido-7-[2-(diethylamino)ethoxy]-6-thiophen-2-yl-1-benzothiophene-3-carboxylate Chemical compound C=1C=C2C(C(=O)OCC)=C(NC(C)=O)SC2=C(OCCN(CC)CC)C=1C1=CC=CS1 JIWVWHCOWHIRFV-UHFFFAOYSA-N 0.000 description 2
- GMOGWHHSRSFSBW-UHFFFAOYSA-N ethyl 2-acetamido-7-[2-(diethylamino)ethoxy]-6-thiophen-3-yl-1-benzothiophene-3-carboxylate Chemical compound C=1C=C2C(C(=O)OCC)=C(NC(C)=O)SC2=C(OCCN(CC)CC)C=1C=1C=CSC=1 GMOGWHHSRSFSBW-UHFFFAOYSA-N 0.000 description 2
- CDYVTVLXEWMCHU-UHFFFAOYSA-N ethyl 2-amino-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate Chemical compound C1CCCC2=C1SC(N)=C2C(=O)OCC CDYVTVLXEWMCHU-UHFFFAOYSA-N 0.000 description 2
- JCEGMKQVUBIBCV-UHFFFAOYSA-N ethyl 2-amino-7-[2-(diethylamino)ethoxy]-6-(4-hydroxyphenyl)-1-benzothiophene-3-carboxylate Chemical compound C=1C=C2C(C(=O)OCC)=C(N)SC2=C(OCCN(CC)CC)C=1C1=CC=C(O)C=C1 JCEGMKQVUBIBCV-UHFFFAOYSA-N 0.000 description 2
- NPGSGJIETGWZON-UHFFFAOYSA-N ethyl 2-amino-7-[2-(diethylamino)ethoxy]-6-(4-methoxyphenyl)-1-benzothiophene-3-carboxylate Chemical compound C=1C=C2C(C(=O)OCC)=C(N)SC2=C(OCCN(CC)CC)C=1C1=CC=C(OC)C=C1 NPGSGJIETGWZON-UHFFFAOYSA-N 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- YNVOMSDITJMNET-UHFFFAOYSA-M thiophene-3-carboxylate Chemical compound [O-]C(=O)C=1C=CSC=1 YNVOMSDITJMNET-UHFFFAOYSA-M 0.000 description 2
- 208000013076 thyroid tumor Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 206010055031 vascular neoplasm Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- QXBWTYBCNFKURT-UHFFFAOYSA-N (2-methylsulfanylphenyl)boronic acid Chemical compound CSC1=CC=CC=C1B(O)O QXBWTYBCNFKURT-UHFFFAOYSA-N 0.000 description 1
- BJQCPCFFYBKRLM-UHFFFAOYSA-N (3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1 BJQCPCFFYBKRLM-UHFFFAOYSA-N 0.000 description 1
- COIQUVGFTILYGA-UHFFFAOYSA-N (4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C=C1 COIQUVGFTILYGA-UHFFFAOYSA-N 0.000 description 1
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- KFHHPVVJLXPHJL-UPHRSURJSA-N (z)-4-hydroperoxy-4-oxobut-2-enoic acid Chemical compound OOC(=O)\C=C/C(O)=O KFHHPVVJLXPHJL-UPHRSURJSA-N 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- HTFXWAOSQODIBI-UHFFFAOYSA-N 2-benzyl-1,3-dihydropyrrolo[3,4-c]pyridine Chemical compound C1C2=CC=NC=C2CN1CC1=CC=CC=C1 HTFXWAOSQODIBI-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-M 4-aminobenzenesulfonate Chemical compound NC1=CC=C(S([O-])(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-M 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- 101150073922 ATG12 gene Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101000950671 Chelon ramada Myosin light chain 3, skeletal muscle isoform Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101001052506 Homo sapiens Microtubule-associated proteins 1A/1B light chain 3A Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102000028677 Rab9 Human genes 0.000 description 1
- 108050007276 Rab9 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000665138 Rattus norvegicus DNA-binding protein SMUBP-2 Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 101000755462 Yarrowia lipolytica (strain CLIB 122 / E 150) Alkaline extracellular protease Proteins 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- RIIPFHVHLXPMHQ-UHFFFAOYSA-N [4-(dimethylamino)phenyl]boronic acid Chemical compound CN(C)C1=CC=C(B(O)O)C=C1 RIIPFHVHLXPMHQ-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000004036 acetal group Chemical group 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 150000002244 furazanes Chemical class 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004142 macroautophagy Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical compound [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- ARYHTUPFQTUBBG-UHFFFAOYSA-N thiophen-2-ylboronic acid Chemical compound OB(O)C1=CC=CS1 ARYHTUPFQTUBBG-UHFFFAOYSA-N 0.000 description 1
- QNMBSXGYAQZCTN-UHFFFAOYSA-N thiophen-3-ylboronic acid Chemical compound OB(O)C=1C=CSC=1 QNMBSXGYAQZCTN-UHFFFAOYSA-N 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- IAQRGUVFOMOMEM-ONEGZZNKSA-N trans-but-2-ene Chemical group C\C=C\C IAQRGUVFOMOMEM-ONEGZZNKSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
<1> 下記一般式(1):
で表されるベンゾチオフェン化合物を有効成分とするオルタナティブオートファジー誘導剤。
<2> 下記一般式(1):
で表されるベンゾチオフェン化合物を細胞に導入する工程を含む、オルタナティブオートファジーを誘導するための方法。
<3> 下記(a)及び(b)からなる群から選択される少なくとも一つのベンゾチオフェン化合物
(a) 下記一般式(1):
で表されるベンゾチオフェン化合物
(b) 前記一般式(1):
[式(1)中、R1は、ハロゲン原子を示す。R2は、ハロゲン原子、水酸基、又は−O−R6−R7で表わされる基を示す。R3は、水素原子で表わされる基を示す。R4は、炭素数が1〜6である直鎖状、分岐状又は環状のアルキル基を示す。R5は、酸素原子又はイミノ基を示す。また式(1)中、R6は、炭素数が1〜6である直鎖状、分岐状又は環状のアルキレン基を示す。R7は、炭素数が1〜6である直鎖状、分岐状若しくは環状のアルキル基、炭素数が2〜6である直鎖状、分岐状若しくは環状のアルケニル基、又は炭素数が1〜6である直鎖状、分岐状若しくは環状のヒドロキシアルキル基で置換されていてもよいアミノ基を示す。]
で表されるベンゾチオフェン化合物。
<4> <3>に記載のベンゾチオフェン化合物を有効成分とする抗癌剤。
<5> <3>に記載のベンゾチオフェン化合物を患者に投与する工程を含む、癌を治療するための方法。
<6> 下記(a)の工程を含む、抗癌活性を有する化合物をスクリーニングするための方法
(a)蛍光タンパク質が付加しているリソソームタンパク質を発現している細胞と、被験化合物とを接触させ、前記リソソームタンパク質の凝集による蛍光輝点の発生を指標として、オルタナティブオートファジーを誘導する活性を有する化合物を選択する工程。
<7> 下記(b)の工程をさらに含む、<6>に記載の方法
(b)細胞と被験化合物とを接触させ、接触後の前記細胞の生存率を指標として、細胞死を誘導する活性を有する化合物を選択する工程。
<8> 工程(b)において、前記細胞が初代培養細胞及び不死化細胞であり、前記初代培養細胞の生存率が80%以上であり、且つ前記不死化細胞の生存率が30%以下であることを前記指標とする、<7>に記載の方法。
<9> 工程(b)において、前記細胞がアポトーシス抵抗性細胞であり、前記生存率が20%以下であることを前記指標とする、<7>に記載の方法。
<10> 下記(c)の工程をさらに含む、<7>〜<9>のいずれか一に記載の方法
(c)工程(a)においてオルタナティブオートファジーを誘導する活性を有する化合物として選択され、且つ工程(b)において細胞死を誘導する活性を有する化合物として選択された化合物を、担癌非ヒト動物に導入し、当該担癌非ヒト動物が担持する癌の大きさを測定し、得られた測定値が、当該被験化合物を導入していない担癌非ヒト動物が担持する癌の大きさの測定値より小さい場合、当該被験化合物を抗癌活性を有する化合物として選択する工程。
で表されるベンゾチオフェン化合物を有効成分とするオルタナティブオートファジー誘導剤である。
[式(1)中、R1は、置換基を有していてもよい5〜10員環の芳香族炭素環又は置換基を有していてもよい5〜10員環の芳香族複素環を示す。R2は、ハロゲン原子、水酸基、−O−R6−R7、又は−O−R6−R8で表わされる基を示す。R3は、水素原子又は−C(=O)R9で表わされる基を示す。R4は、炭素数が1〜6である直鎖状、分岐状又は環状のアルキル基を示す。R5は、酸素原子又はイミノ基を示す。また式(1)中、R6は、炭素数が1〜6である直鎖状、分岐状又は環状のアルキレン基を示す。R7は、炭素数が1〜6である直鎖状、分岐状若しくは環状のアルキル基、炭素数が2〜6である直鎖状、分岐状若しくは環状のアルケニル基、又は炭素数が1〜6である直鎖状、分岐状若しくは環状のヒドロキシアルキル基で置換されていてもよいアミノ基を示す。R8は、置換基を有していてもよい5〜10員環の芳香族炭素環又は置換基を有していてもよい5〜10員環の芳香族複素環を示す。R9は、炭素数が1〜6である直鎖状、分岐状若しくは環状のアルキル基、置換基を有していてもよい5〜10員環の芳香族炭素環、又は置換基を有していてもよい5〜10員環の芳香族複素環を示す。]
で表されるベンゾチオフェン化合物
(b) 前記一般式(1):
[式(1)中、R1は、ハロゲン原子を示す。R2は、ハロゲン原子、水酸基、又は−O−R6−R7で表わされる基を示す。R3は、水素原子で表わされる基を示す。R4は、炭素数が1〜6である直鎖状、分岐状又は環状のアルキル基を示す。R5は、酸素原子又はイミノ基を示す。また式(1)中、R6は、炭素数が1〜6である直鎖状、分岐状又は環状のアルキレン基を示す。R7は、炭素数が1〜6である直鎖状、分岐状若しくは環状のアルキル基、炭素数が2〜6である直鎖状、分岐状若しくは環状のアルケニル基、又は炭素数が1〜6である直鎖状、分岐状若しくは環状のヒドロキシアルキル基で置換されていてもよいアミノ基を示す。]
で表されるベンゾチオフェン化合物。
本発明の抗癌活性を有する化合物をスクリーニングするための方法は、
(a)蛍光タンパク質が付加しているリソソームタンパク質を発現している細胞と、被験化合物とを接触させ、前記リソソームタンパク質の凝集による蛍光輝点の発生を指標として、オルタナティブオートファジーを誘導する活性を有する化合物を選択する工程
を含む方法である。
本発明の抗癌活性を有する化合物をスクリーニングするための方法において、前記工程(a)に加え、さらに、細胞と被験化合物とを接触させ、接触後の前記細胞の生存率を指標として、細胞死を誘導する活性を有する化合物を選択する工程(工程(b))を含むことが好ましい。これにより、より効率的に抗癌活性の高い化合物をスクリーニングすることができる。
本発明の抗癌活性を有する化合物をスクリーニングするための方法において、前記工程(a)及び工程(b)に加え、さらに、工程(a)においてオルタナティブオートファジーを誘導する活性を有する化合物として選択され、且つ工程(b)において細胞死を誘導する活性を有する化合物として選択された化合物を、担癌非ヒト動物に導入し、当該担癌非ヒト動物が担持する癌の大きさを測定し、得られた測定値が、当該被験化合物を導入していない担癌非ヒト動物が担持する癌の大きさの測定値より小さい場合、当該被験化合物を抗癌活性を有する化合物として選択する工程(工程(c))を含むことが好ましい。これにより、より効率良く、抗癌活性の高い化合物をスクリーニングでき、さらには生存率の改善、転移の有無等を併せて調べることにより、実際の癌治療・予防効果も予測できる。
東京医科歯科大学ケミカルバイオロジースクリーニングセンター(http://www.tmd.ac.jp/mri/SBS/cbsc/CopyPlateList/CopyPlate.html)から提供を受けた11588種の化合物を被験化合物とし、以下に示す方法にて、リソソームタンパク質の凝集による蛍光輝点の発生を指標として、オルタナティブオートファジーを誘導する活性を有する化合物を選択した。
先ず、ATG5欠損マウス胎児線維芽細胞(「ATG5−KO MEF」とも称する)にレトロウィルスを用いて、Lamp1とGFPとの融合タンパク質(「Lamp1−GFP」とも称する)を発現する遺伝子を導入した。そして、Lamp1−GFPの発現の高い細胞をクローニングし、Lamp1−GFP/ATG5−KO MEFとして調製した。
Lamp1−GFP発現細胞において生じるオーファジーの程度、すなわち1細胞あたりのLamp1−GFPの凝集が占める面積と、Lamp1−GFPの凝集による蛍光輝点の蛍光強度とが相関しているかどうかを調べた。
前日に1×104/96wellになるよう播種したLamp1−GFP/ATG5−KO MEFに、被験化合物を最終濃度50μMとなるよう添加し、37℃、10%CO2にて5時間培養した。
東京医科歯科大学ケミカルバイオロジースクリーニングセンターから提供を受けた11588種の化合物を被験化合物とし、以下に示す方法にて、細胞の生存率を指標として、細胞死を誘導する活性を有する化合物を選択した。
本実施例においては、増殖速度の遅い初代培養野生型MEF(primary MEF)と、SV40T抗原を導入することにより不死化した、増殖速度の速いtransformed MEFとを用いて、がん細胞特異的に細胞死を誘導する化合物の選択を行った。すなわち、先ず、transformed MEFを2x104/well、primary MEFを4x104/wellになるように、96wellプレートに播種した。そして、その翌日に、化合物を最終濃度50μMとなるよう添加し、37℃、10%CO2にて24時間培養した。次いで、Cell titer blue(CTB)(Promega社製)を添付のプロトコールの通りに使用し、各被験化合物と接触させた細胞の生存率を測定した。そして、transformed MEFで細胞死を大きく誘導し(生存率30%以下)、primary MEFで細胞死を誘導しない(生存率80%以上)被験化合物を、がん細胞特異的に細胞死を誘導する化合物として選択した。その結果、実施例2においては、供した11588種の化合物のうち、411化合物が選択された。
前記11588種の化合物のうち、実施例1において選択され、かつ実施例2においても選択された24化合物を被験化合物とし、以下に示す担癌非ヒト動物を用いた方法にて、抗癌活性を有する化合物を選択した。
p53欠損C57/B6Jマウスに自然発生した腫瘍より樹立した腫瘍細胞株(「53T」とも称する)を、野生型C57/B6Jマウスの腹側皮内4箇所に3x105細胞ずつ移植し、翌日より隔日で5回、各化合物をマウスに投与した。各化合物の濃度は0.4μmol/(50μl DMSO+100μl PBS)/匹/回とした。また陰性対照群として、同量のDMSOのみを投与したものも用意した。そして、移植後21日(3週間)のマウスの腫瘍径を計測し、腫瘍体積を算出して対照群との比較を行った。得られた結果を図2に示す。なお図2中、縦軸は腫瘍体積の平均値(mm3)を示し、1000mm2付近の横軸に平行な線は、陰性対照群における腫瘍体積の平均値を示す。
実施例3において選択された chem09及びchem13について、以下に示す腫瘍細胞株を用いた方法にて、これらのオルタナティブオートファジー誘導活性を確認した。
前述のLamp1−GFP/ATG5−KO MEFを用いた<オルタナティブオートファジー誘導活性の評価>と同様にして、p53欠損C57/B6Jマウスに自然発生した腫瘍より樹立した腫瘍細胞株(「53T」とも称する)に化合物#09又は#13を最終濃度20μMとなるように培養液に添加し、その6時間後に蛍光顕微鏡及び電子顕微鏡にて観察した。なお、本評価においては、Lamp1の代わりにLamp2を用いた。得られた結果を図3〜6に示す。
以下に示す腫瘍細胞株を用いた方法にて、化合物#09及び#13の抗癌活性を確認した。
先ず、マウス腫瘍細胞株 53Tを2x104/wellになるように、96wellプレートに播種した。そして、その翌日に、DMSOに溶解させた化合物#09又は♯13を最終濃度1、5、10、20又は50μMとなるように添加した。また、陰性対照としてDMSOのみを添加したものも用意した。次いで、37℃、10%CO2にて24時間培養した後、Cell titer blue(CTB)(Promega社製)を添付のプロトコールの通りに使用し、CTB試薬を添加してから10分後の各細胞の蛍光発色量を、化合物#09又は♯13と接触させた細胞におけるCTB計測値として、かかる計測値に基づき、下記式にて化合物#09及び♯13の細胞死誘導率を算出した。
得られた結果を表1に示す。
化合物#09及び#13について、以下に示す正常細胞及び癌細胞を用いた方法にて、これらの細胞死を誘導する活性が、癌細胞に対して特異的なものであるかどうかを調べた。
前述の<in vitroにおける抗癌活性の評価>と同様にして、初代線維芽細胞(正常細胞)又はSV40で不死化した線維芽細胞(癌細胞)に、化合物#09又は#13を最終濃度20μMとなるように培養液に添加して得られたCTB計測値に基づき、細胞生存率を経時的に算出した。なお、細胞生存率は、1−細胞死誘導率とした。得られた結果を図7及び8に示す。
以下に示す担癌マウスを用いた方法にて、化合物#09及び#13のin vivoにおける抗癌活性を確認した。
53Tを、野生型C57/B6Jマウスの腹側皮内4箇所に3x105細胞ずつ移植し、翌日より隔日で5回、化合物#09又は#13を、0(DMSOのみ)、5、10又は20μMにて、マウス6匹ずつに投与した。そして、移植後21日(3週間)のマウスの腫瘍径を計測し、腫瘍体積を算出した。得られた結果を図9及び11に示す。なお、図9及び11において、各点は、マウス1匹における4カ所の腫瘍の平均体積を表わす。
以下に示す方法にて、化合物♯09及び#13について、各化合物を投与した担癌マウスの生存率を調べた。また対照として既に臨床にて抗癌剤として使用されているエトポシド(etoposide)も担癌マウスに投与し、その生存率を調べた。すなわち、前述の<in vivoにおける、抗癌活性を有する化合物の選択>と同様にして、野生型C57/B6Jマウスの腹側皮内4箇所に3x105細胞ずつ53Tをマウスに移植し、その翌日より隔日にて5回、化合物#09又は#13を10μMにて担癌マウス12匹ずつに投与した。また、対照としてエトポシドも10μMにて担癌マウスに投与した。さらに、陰性対照としてDMSOを投与した群も調製した。そして、これら担癌マウスの生存率を調べ、各化合物投与後の生存曲線を得た。得られた結果を図13〜15に示す。
化合物#09及びその類似化合物について、実施例1に記載の方法と同様の方法にて、各化合物のオルタナティブオートファジー誘導能を評価した。また、これら化合物について、実施例5に記載の方法と同様の方法にて、各化合物の抗癌活性を評価した。得られた結果を図16及び17に示す。化合物#09及びその類似化合物の構造は以下の通りである。なお、これら類似化合物は、Pharmeks社(ロシア)から購入した。
化合物#09の類似化合物として、下記構造式からなる新規ベンゾチオフェン化合物(TMD−459及びTMD−460)を設計し、合成した。
(1) クロマトグラフィー
分析用薄層クロマトグラフィー(TLC)は、あらかじめシリカゲルが塗布されたガラスプレート(MERCK 5715、silica gel 60 F254)を用いて行った。スポット検出は、紫外線ランプ(254nm)、ヨウ素吸着、過マンガン酸カリウム水溶液による呈色によって行った。
1H核磁気共鳴(NMR)スペクトル(500MHz)は、Bruker社製、AVANCE500核磁気共鳴装置を用いて測定した。化学シフト(δ)は、tetramethylsilane((CH3)4Si)(CDCl3中での測定;0ppm)又は測定溶媒の非重水素化体由来のピーク(CD3ODでの測定:3.31ppm;DMSO−d6での測定:2.49ppm)を内部標準として相対的値として表した。シグナル***線様式の略語s、d、t、q、m、brはそれぞれ単重線、二重線、三重線、四重線、多重線、幅広線を表す。
すべての試薬は特に記さない限り、市販のものをそのまま使用した。反応、抽出、クロマトグラフィー用の溶媒には、酢酸エチル、n−ヘキサン、脱水ジクロロメタン、脱水テトラヒドロフラン(THF)、メタノール、1,4−ジオキサン、酢酸、N,N−ジメチルホルムアミド(DMF)の市販品をそのまま用いた。
t,J=7.0Hz,6H),1.50(t,J=7.0Hz,3H),2.36(s,3H),2.70−2.79(br,4H),3.04−3.09(br,2H),4.27(t,J=6.5Hz,2H),4.48(q,J=7.0Hz,2H),7.53(d,J=8.5Hz,1H),7.88(d,J=8.5Hz,1H),11.70(br s,1H);13C NMR(126MHz,CDCl3)δ 11.9,14.6,24.1,47.8,52.6,61.5,71.6(br),106.6,110.3,120.4,129.1,131.1,135.3,150.5,153.1,166.6,168.3。
TMD−460及び化合物#09の細胞死を誘導する活性を、以下に示す方法にて評価した。
得られた結果を表2に示す。
化合物#09の類似化合物として、下記構造式からなる新規ベンゾチオフェン化合物(TMD−473、TMD−511〜TMD−520、TMD−593及びTMD−594)を設計し、合成した。
化合物#09及びその類似化合物(TMD−473、TMD−511〜TMD−520、TMD−593及びTMD−594)について、実施例1に記載の方法と同様の方法にて、各化合物のオルタナティブオートファジー誘導能を評価した。得られた結果を図18に示す。
Claims (10)
- 下記一般式(1):
で表されるベンゾチオフェン化合物を有効成分とするオルタナティブオートファジー誘導剤。 - 下記一般式(1):
で表されるベンゾチオフェン化合物を細胞に導入する工程を含む、オルタナティブオートファジーを誘導するための方法。 - 下記(a)及び(b)からなる群から選択される少なくとも一つのベンゾチオフェン化合物
(a) 下記一般式(1):
で表されるベンゾチオフェン化合物
(b) 前記一般式(1):
[式(1)中、R1は、ハロゲン原子を示す。R2は、ハロゲン原子、水酸基、又は−O−R6−R7で表わされる基を示す。R3は、水素原子で表わされる基を示す。R4は、炭素数が1〜6である直鎖状、分岐状又は環状のアルキル基を示す。R5は、酸素原子又はイミノ基を示す。また式(1)中、R6は、炭素数が1〜6である直鎖状、分岐状又は環状のアルキレン基を示す。R7は、炭素数が1〜6である直鎖状、分岐状若しくは環状のアルキル基、炭素数が2〜6である直鎖状、分岐状若しくは環状のアルケニル基、又は炭素数が1〜6である直鎖状、分岐状若しくは環状のヒドロキシアルキル基で置換されていてもよいアミノ基を示す。]
で表されるベンゾチオフェン化合物。 - 請求項3に記載のベンゾチオフェン化合物を有効成分とする抗癌剤。
- 請求項3に記載のベンゾチオフェン化合物を患者に投与する工程を含む、癌を治療するための方法。
- 下記(a)の工程を含む、抗癌活性を有する化合物をスクリーニングするための方法
(a)蛍光タンパク質が付加しているリソソームタンパク質を発現している細胞と、被験化合物とを接触させ、前記リソソームタンパク質の凝集による蛍光輝点の発生を指標として、オルタナティブオートファジーを誘導する活性を有する化合物を選択する工程。 - 下記(b)の工程をさらに含む、請求項6に記載の方法
(b)細胞と被験化合物とを接触させ、接触後の前記細胞の生存率を指標として、細胞死を誘導する活性を有する化合物を選択する工程。 - 工程(b)において、前記細胞が初代培養細胞及び不死化細胞であり、前記初代培養細胞の生存率が80%以上であり、且つ前記不死化細胞の生存率が30%以下であることを前記指標とする、請求項7に記載の方法。
- 工程(b)において、前記細胞がアポトーシス抵抗性細胞であり、前記生存率が20%以下であることを前記指標とする、請求項7に記載の方法。
- 下記(c)の工程をさらに含む、請求項7〜9のいずれか一項に記載の方法
(c)工程(a)においてオルタナティブオートファジーを誘導する活性を有する化合物として選択され、且つ工程(b)において細胞死を誘導する活性を有する化合物として選択された化合物を、担癌非ヒト動物に導入し、当該担癌非ヒト動物が担持する癌の大きさを測定し、得られた測定値が、当該被験化合物を導入していない担癌非ヒト動物が担持する癌の大きさの測定値より小さい場合、当該被験化合物を抗癌活性を有する化合物として選択する工程。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012026373 | 2012-02-09 | ||
JP2012026373 | 2012-02-09 | ||
JP2012026377 | 2012-02-09 | ||
JP2012026377 | 2012-02-09 | ||
PCT/JP2013/052947 WO2013118842A1 (ja) | 2012-02-09 | 2013-02-07 | ベンゾチオフェン化合物、該化合物を有効成分とするオルタナティブオートファジー誘導剤及び抗癌剤、並びに抗癌活性を有する化合物をスクリーニングするための方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2013118842A1 true JPWO2013118842A1 (ja) | 2015-05-11 |
JP6124409B2 JP6124409B2 (ja) | 2017-05-10 |
Family
ID=48947597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013557579A Active JP6124409B2 (ja) | 2012-02-09 | 2013-02-07 | ベンゾチオフェン化合物、該化合物を有効成分とするオルタナティブオートファジー誘導剤及び抗癌剤、並びに抗癌活性を有する化合物をスクリーニングするための方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10954222B2 (ja) |
EP (1) | EP2813226B1 (ja) |
JP (1) | JP6124409B2 (ja) |
WO (1) | WO2013118842A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022111829A1 (en) | 2020-11-30 | 2022-06-02 | Symrise Ag | Essential oils of citrus fruits for use as medicament for induced, increased and/or accelerated autophagy in human keratinocytes |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007153792A (ja) * | 2005-12-05 | 2007-06-21 | Nippon Kayaku Co Ltd | 新規なdnaメチルトランスフェラーゼ阻害剤 |
JP2008532486A (ja) * | 2005-02-01 | 2008-08-21 | レ ラボラトワール セルヴィエ | BCL−2タンパク質ファミリーの抗アポトーシスメンバーと相互作用するベクリン(Beclin)タンパク質のモチーフ、およびその使用 |
JP2009124996A (ja) * | 2007-11-22 | 2009-06-11 | National Institute Of Information & Communication Technology | オートファジーの誘導方法、及び培養細胞への外来粒子導入方法 |
WO2009123145A1 (ja) * | 2008-03-31 | 2009-10-08 | 福岡県 | パラスポリン-1受容体及びその用途 |
WO2011019082A1 (ja) * | 2009-08-10 | 2011-02-17 | 独立行政法人科学技術振興機構 | オートファジーの測定方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6268137B1 (en) * | 1996-05-22 | 2001-07-31 | Methylgene, Inc. | Specific inhibitors of DNA methyl transferase |
US5972639A (en) * | 1997-07-24 | 1999-10-26 | Irori | Fluorescence-based assays for measuring cell proliferation |
DE60312997T2 (de) * | 2002-06-06 | 2007-12-13 | Smithkline Beecham Corp. | Nf-kb-inhibitoren |
US20080269259A1 (en) * | 2005-01-19 | 2008-10-30 | The Trustees Of The University Of Pennsylvania | Regulation of Autophagy and Cell Survival |
RU2474612C2 (ru) * | 2008-05-20 | 2013-02-10 | Инкурон ЛЛК | Индуцирование гибели клеток путем ингибирования адаптивного теплового шокового ответа |
-
2013
- 2013-02-07 JP JP2013557579A patent/JP6124409B2/ja active Active
- 2013-02-07 US US14/376,671 patent/US10954222B2/en active Active
- 2013-02-07 EP EP13746448.3A patent/EP2813226B1/en active Active
- 2013-02-07 WO PCT/JP2013/052947 patent/WO2013118842A1/ja active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008532486A (ja) * | 2005-02-01 | 2008-08-21 | レ ラボラトワール セルヴィエ | BCL−2タンパク質ファミリーの抗アポトーシスメンバーと相互作用するベクリン(Beclin)タンパク質のモチーフ、およびその使用 |
JP2007153792A (ja) * | 2005-12-05 | 2007-06-21 | Nippon Kayaku Co Ltd | 新規なdnaメチルトランスフェラーゼ阻害剤 |
JP2009124996A (ja) * | 2007-11-22 | 2009-06-11 | National Institute Of Information & Communication Technology | オートファジーの誘導方法、及び培養細胞への外来粒子導入方法 |
WO2009123145A1 (ja) * | 2008-03-31 | 2009-10-08 | 福岡県 | パラスポリン-1受容体及びその用途 |
WO2011019082A1 (ja) * | 2009-08-10 | 2011-02-17 | 独立行政法人科学技術振興機構 | オートファジーの測定方法 |
Non-Patent Citations (4)
Title |
---|
A.N.GRINEV ET AL.: "Synthesis of derivatives of 2-acylamino-7-oxybenzo[b]thiophene. Bromination and Nitration", CHEMISTRY OF HETEROCYCLIC COMPOUNDS(ISSN 0009-3122), vol. 23, no. 4, JPN6017005515, October 1987 (1987-10-01), pages 384 - 386, XP002736470, ISSN: 0003503074, DOI: 10.1007/BF00546729 * |
INAMI,Y. ET AL: "Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells", J CELL BIOL, vol. 193, no. 2, JPN6013014783, 2011, pages 275 - 284, ISSN: 0003503072 * |
M.V.KAPUSTINA ET AL.: "Synthesis 6-formylbenzo(b)thiophene derivatives and their antiviral activity", PHARMACEUTICAL CHEMISTRY JOURNAL (ISSN 0091-150X), JPN6017005514, September 1992 (1992-09-01), pages 789 - 792, ISSN: 0003503073 * |
NISHIDA,Y. ET AL: "Discovery of Atg5/Atg7-independent alternative macroautophagy", NATURE, vol. 461, no. 7264, JPN6013014781, 2009, pages 654 - 658, XP037707736, ISSN: 0003433952, DOI: 10.1038/nature08455 * |
Also Published As
Publication number | Publication date |
---|---|
US20150056141A1 (en) | 2015-02-26 |
EP2813226A4 (en) | 2015-08-05 |
WO2013118842A1 (ja) | 2013-08-15 |
JP6124409B2 (ja) | 2017-05-10 |
US10954222B2 (en) | 2021-03-23 |
EP2813226A1 (en) | 2014-12-17 |
EP2813226B1 (en) | 2016-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108368104B (zh) | Yap/taz-tead相互作用的新化合物抑制剂及其在治疗恶性间皮瘤中的用途 | |
KR102534185B1 (ko) | 비아릴 유도체, 이의 합성법과 그 약학적 용법 | |
CN110114075B (zh) | 含有二硫化物的细胞穿透肽及其制备和使用方法 | |
Hay et al. | Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains | |
Abdelbaset et al. | Discovery of novel thienoquinoline-2-carboxamide chalcone derivatives as antiproliferative EGFR tyrosine kinase inhibitors | |
CN1807413B (zh) | 咔唑磺酰胺衍生物及其制备方法 | |
ES2787599T3 (es) | Inhibidores de leucemia inv(16) | |
CN105358549B (zh) | 喹唑啉衍生物 | |
Dolciami et al. | Binding mode and structure–activity relationships of ITE as an aryl hydrocarbon receptor (AhR) agonist | |
JP2018508563A (ja) | Usp7阻害剤化合物及び使用方法 | |
Li et al. | Design and biological evaluation of novel triaryl pyrazoline derivatives with dioxane moiety for selective BRAFV600E inhibition | |
CN107459476B (zh) | 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途 | |
Guo et al. | Molecular hybrid design, synthesis, in vitro and in vivo anticancer evaluation, and mechanism of action of N-acylhydrazone linked, heterobivalent β-carbolines | |
Jiang et al. | Targeting the N terminus of eIF4AI for inhibition of its catalytic recycling | |
Ma et al. | Discovery of novel N-sulfonamide-tetrahydroisoquinolines as potent retinoic acid receptor-related orphan receptor γt agonists | |
WO2010108058A2 (en) | Small molecule inhibitors of dusp6 and uses therefor | |
CN107721975A (zh) | 具有抗肿瘤活性的brd4小分子抑制剂、合成方法及其应用 | |
CA3190787A1 (en) | Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity | |
JP6124409B2 (ja) | ベンゾチオフェン化合物、該化合物を有効成分とするオルタナティブオートファジー誘導剤及び抗癌剤、並びに抗癌活性を有する化合物をスクリーニングするための方法 | |
JP2021509399A (ja) | インドールアミン−2,3−ジオキシゲナーゼ阻害剤およびその調製方法と使用 | |
US11912663B2 (en) | Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses | |
Takada et al. | Identification of 2, 6-Disubstituted 3 H-Imidazo [4, 5-b] pyridines as Therapeutic Agents for Dysferlinopathies through Phenotypic Screening on Patient-Derived Induced Pluripotent Stem Cells | |
JP6021148B2 (ja) | Lst−1及び/又はlst−2によって輸送される化合物 | |
CN104159889B (zh) | 介导刺猬蛋白信号通路的新化合物、其标记的形式和应用 | |
Liu et al. | Synthesis, in vitro cytotoxicity and biological evaluation of twenty novel 1, 3-benzenedisulfonyl piperazines as antiplatelet agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160205 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161205 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170306 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170331 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6124409 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |